BioShockers'  Instablog

Send Message is a recently created biotech investing website that is focused on finding high-potential, low-price, and legitimate biotech/pharma companies. The great majority of stocks we will do write-ups on will be on one of three exchanges, NASDAQ, AMEX, or NYSE. Occasionally, we will... More
  • Delcath Systems - Oversold & Undervalued 1 comment
    May 9, 2010 12:00 AM | about stocks: DCTH
    We believe that DCTH (Delcath Systems, Inc.) is a biotech to keep an eye on. Delcath recently released top-line (basically an overview of the trial) results of their phase 3 trial using the Delcath PHP System in melanoma metastases in the liver. The trial surpassed primary endpoint expectations. The day after the positive trial results were released (April 22), Roth Capital initiated coverage with a "Buy" rating and a $15 target -- four days later (April 26), Roth Capital upped their target to $20, saying:

    "Last week co. reported positive data on its PHP System. Analyst Matthew Pommer tells salesforce, based on his feedback from the field, came away content that data from the phase III study will lead to significant conversion of patients to therapy with the PHP System for both cutaneous and ocular melanoma that is metastatic to the liver (i.e., the "on-label" population). Says, in particular, he expects most high-volume academic cancer centers in US to convert the bulk of these patients to PHP therapy. Ups $15 target to $20, reiterates buy./B.Brodie."

    Full, detailed data will be released at ASCO this June, which could lead to a runup in anticipation of the presentation.

    In the past week, Delcath shares have gone from the $15 range into the $12 range, and we plan to open a position sometime in the near future.

    Delcath can also be a good growth story, in our opinion. Due to the positive results of this phase 3 trial, and if the PHP System is approved, Delcath should be able to expand the product label into other liver cancers.

    Of course, this is all in our opinion. Please read our disclaimer in our bio before investing in any stock that we do a write-up on. is a recently created investment website, with a fully functional FDA Calendar, Blog, and Research on Biotech Stocks.

    Disclosure: No positions
    Stocks: DCTH
Back To BioShockers' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • cats
    , contributor
    Comments (17) | Send Message
    I am a PhD scientist and investor. DCTH hit a home run on their Phase 3 trials which were released in a very brief form recently. Their more complete results will be presented by Dr. Pingpank of the National Institute of Health & the U of Pittsburg at the June 5 ASCO Conference. Expect DCTH's application to the FDA shortly after that. FDA already jumped them from Phase 1 to Phase 3 earlier. ABC TV evening news ran a story on DCTH about a year ago. After ASCO, watch for numerous TV interviews. I have a significant long position in this stock.
    9 May 2010, 07:11 PM Reply Like
Full index of posts »
Latest Followers

Latest Comments

Most Commented
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.